Goldman Sachs Group Inc. Trims Stock Holdings in Harrow, Inc. $HROW

Key Points

• Goldman Sachs Group Inc. reduced its stake in Harrow, Inc. by 37.4% in Q1, now holding approximately 0.35% of the company, worth about $3.4 million.
• Harrow reported quarterly earnings of $0.24 per share, significantly surpassing analysts' expectations of $0.01, though falling short on revenue estimates with $63.74 million compared to $64.23 million predicted.
• Equities analysts project a moderate buy sentiment on Harrow's stock, with a consensus price target of $64.67 amid several upgrades from different research firms.

Goldman Sachs Group Inc. trimmed its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 37.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 127,783 shares of the company's stock after selling 76,264 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.35% of Harrow worth $3,399,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HROW. GF Fund Management CO. LTD. acquired a new stake in Harrow during the 4th quarter worth about $25,000. Quarry LP acquired a new position in shares of Harrow during the 1st quarter worth approximately $32,000. State of Wyoming acquired a new position in Harrow in the first quarter valued at approximately $97,000. Strs Ohio acquired a new position in Harrow during the first quarter worth $149,000. Finally, GAMMA Investing LLC lifted its stake in Harrow by 2,401.2% during the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after purchasing an additional 6,027 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Up 5.2%

HROW stock opened at $45.38 on Friday. Harrow, Inc. has a 12-month low of $20.85 and a 12-month high of $59.23. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -181.52 and a beta of 0.33. The company has a 50 day moving average of $37.09 and a two-hundred day moving average of $30.45.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Zacks Research lowered Harrow from a "strong-buy" rating to a "hold" rating in a report on Friday, September 12th. William Blair assumed coverage on shares of Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating for the company. HC Wainwright increased their target price on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. BTIG Research lifted their price objective on Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Cantor Fitzgerald initiated coverage on Harrow in a research report on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $64.67.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.